Saltar al contenido
Merck

Evidence-based morphine dosing for postoperative neonates and infants.

Clinical pharmacokinetics (2014-02-06)
Elke H J Krekels, Dick Tibboel, Saskia N de Wildt, Ilse Ceelie, Albert Dahan, Monique van Dijk, Meindert Danhof, Catherijne A J Knibbe
RESUMEN

From a previously validated paediatric population pharmacokinetic model, it was derived that non-linear morphine maintenance doses of 5 μg/kg(1.5)/h, with a 50 % dose reduction in neonates with a postnatal age (PNA) <10 days, yield similar morphine and metabolite concentrations across patients younger than 3 years. Compared with traditional dosing, this model-derived dosing regimen yields significantly reduced doses in neonates aged <10 days. Concentration predictions of the population model were prospectively evaluated in postoperative term neonates and infants up to the age of 1 year who received morphine doses according to the model-derived algorithm. The efficacy of this dosing algorithm was evaluated using morphine rescue medication and actual average infusion rates. Morphine and metabolite concentrations were accurately predicted by the paediatric pharmacokinetic morphine model. With regard to efficacy, 5 out of 18 neonates (27.8 %) with a PNA of <10 days needed rescue medication versus 18 of the 20 older patients (90 %) (p = 0.06). The median (interquartile range [IQR]) total morphine rescue dose was 0 (0-20) μg/kg in younger patients versus 193 (19-362) μg/kg in older patients (p = 0.003). The median (IQR) actual average morphine infusion rate was 4.4 (4.0-4.8) μg/kg/h in younger patients versus 14.4 (11.3-23.4) μg/kg/h in older patients (p < 0.001). Morphine paediatric dosing algorithms corrected for pharmacokinetic differences alone yield effective doses that prevent over-dosing for neonates with a PNA <10 days. The fact that many neonates and infants with a PNA ≥10 days still required rescue medication warrants pharmacodynamic studies to further optimize the dosing algorithm for these patients.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Acetonitrilo, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Acetonitrilo, HPLC Plus, ≥99.9%
Sigma-Aldrich
Acetonitrilo, ACS reagent, ≥99.5%
Sigma-Aldrich
Acetonitrilo, anhydrous, 99.8%
Sigma-Aldrich
Acetonitrilo, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Acetonitrilo, suitable for HPLC-GC, ≥99.8% (GC)
Sigma-Aldrich
Acetonitrilo, biotech. grade, ≥99.93%
Sigma-Aldrich
Acetonitrilo, ReagentPlus®, 99%
Sigma-Aldrich
Acetonitrilo, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
Acetonitrilo solution, contains 0.1 % (v/v) formic acid, suitable for HPLC
Sigma-Aldrich
Acetonitrilo solution, contains 0.1 % (v/v) trifluoroacetic acid, suitable for HPLC
Sigma-Aldrich
Acetonitrilo, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
Acetonitrilo, suitable for DNA synthesis, ≥99.9% (GC)
Supelco
Acetonitrilo, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Acetonitrilo, HPLC grade, ≥99.93%
Sigma-Aldrich
Acetonitrilo, ≥99.8%, suitable for HPLC
Supelco
Acetonitrilo, analytical standard
USP
Acetonitrilo solution, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Acetonitrilo, ≥99.8%, for residue analysis, JIS 300
Sigma-Aldrich
Acetonitrilo, JIS special grade, ≥99.5%
Sigma-Aldrich
Acetonitrilo, ≥99.5%, ACS reagent
Supelco
Acetonitrilo, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetonitrilo solution, contains 0.05 % (w/v) ammonium formate, 5 % (v/v) water, 0.1 % (v/v) formic acid, suitable for HPLC
Sigma-Aldrich
Acetonitrilo, SAJ first grade, ≥99.0%
Sigma-Aldrich
Acetonitrilo, for chromatography
Sigma-Aldrich
Acetonitrilo, ≥99.8%, for residue analysis, JIS 1000
Sigma-Aldrich
Acetonitrilo, for residue analysis, JIS 5000
Sigma-Aldrich
Acetonitrilo solution, contains 0.05 % (v/v) trifluoroacetic acid
Sigma-Aldrich
Acetonitrilo solution, contains 10.0% acetone, 0.05% formic acid, 40.0% 2-propanol